Simone Schmitt, PhD

Vice President, Technology & Operations at Memo Therapeutics AG

Speaker

Simone Schmitt became part of Memo Therapeutics AG in 2014, where she played a key role in developing MTx’s high-throughput microfluidic antibody platform. Before joining MTx, she gained experience in building new technologies as a Senior Scientist at Delenex Therapeutics, a company specialized in scFv development. Simone earned her PhD in Protein Biochemistry in the lab of Prof. Dr. Dr. Neupert at LMU Munich.